Report of Foreign Issuer (6-k)
November 14 2019 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: November 2019
Commission file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation of registrant’s name
into English)
14 Einstein Street, Nes Ziona, Israel
7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Financial Statements
The unaudited condensed
consolidated financial statements for Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”),
as of and for the three and nine-month periods ended September 30, 2019 and 2018, and the Operating and Financial Review and
Prospects of Enlivex for the corresponding periods are furnished as Exhibits 99.1 and Exhibit 99.2, respectively, to this Report
on Form 6-K and incorporated by reference into Enlivex’s registration statements on Form F-3 (File No. 333-232413 and File
No. 333-232009 ), filed with the Securities and Exchange Commission.
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Shai Novik
|
|
Name:
|
Shai Novik
|
|
Title:
|
Executive Chairman
|
Date: November 14, 2019
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2024 to May 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From May 2023 to May 2024